Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19 : A Randomized Clinical Trial
Despite the widespread availability of effective vaccines, new cases of infection with severe acute respiratory syndrome coronavirus-2, the cause of coronavirus disease 2019 (COVID-19), remain a concern in the settings of vaccine hesitancy and vaccine breakthrough. In this randomized, controlled, phase 2 trial, we hypothesized that high-dose ascorbic acid delivered intravenously to achieve pharmacologic concentrations may target the high viral phase of COVID-19 and thus improve early clinical outcomes. Sixty-six patients admitted with COVID-19 and requiring supplemental oxygen were randomized to receive either escalating doses of intravenous ascorbic acid plus standard of care or standard of care alone. The demographic and clinical characteristics were well-balanced between the two study arms. The primary outcome evaluated in this study was clinical improvement at 72 h after randomization. While the primary outcome was not achieved, point estimates for the composite outcome and its individual components of decreased use of supplemental oxygen, decreased use of bronchodilators, and the time to discharge were all favorable for the treatment arm. Possible favorable effects of ascorbic acid were most apparent during the first 72 h of hospitalization, although these effects disappeared over the course of the entire hospitalization. Future larger trials of intravenous ascorbic acid should be based on our current understanding of COVID-19 with a focus on the potential early benefits of ascorbic in hospitalized patients.
| Errataetall: |
ErratumIn: Life (Basel). 2022 Aug 31;12(9):. - PMID 36143494 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Life (Basel, Switzerland) - 12(2022), 3 vom: 19. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coppock, Dagan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.02.2024 published: Electronic ErratumIn: Life (Basel). 2022 Aug 31;12(9):. - PMID 36143494 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/life12030453 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338604928 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338604928 | ||
| 003 | DE-627 | ||
| 005 | 20240214232445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/life12030453 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM338604928 | ||
| 035 | |a (NLM)35330204 | ||
| 035 | |a (PII)453 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coppock, Dagan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19 |b A Randomized Clinical Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Life (Basel). 2022 Aug 31;12(9):. - PMID 36143494 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Despite the widespread availability of effective vaccines, new cases of infection with severe acute respiratory syndrome coronavirus-2, the cause of coronavirus disease 2019 (COVID-19), remain a concern in the settings of vaccine hesitancy and vaccine breakthrough. In this randomized, controlled, phase 2 trial, we hypothesized that high-dose ascorbic acid delivered intravenously to achieve pharmacologic concentrations may target the high viral phase of COVID-19 and thus improve early clinical outcomes. Sixty-six patients admitted with COVID-19 and requiring supplemental oxygen were randomized to receive either escalating doses of intravenous ascorbic acid plus standard of care or standard of care alone. The demographic and clinical characteristics were well-balanced between the two study arms. The primary outcome evaluated in this study was clinical improvement at 72 h after randomization. While the primary outcome was not achieved, point estimates for the composite outcome and its individual components of decreased use of supplemental oxygen, decreased use of bronchodilators, and the time to discharge were all favorable for the treatment arm. Possible favorable effects of ascorbic acid were most apparent during the first 72 h of hospitalization, although these effects disappeared over the course of the entire hospitalization. Future larger trials of intravenous ascorbic acid should be based on our current understanding of COVID-19 with a focus on the potential early benefits of ascorbic in hospitalized patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a ascorbic acid | |
| 650 | 4 | |a vitamin C | |
| 700 | 1 | |a Violet, Pierre-Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Vasquez, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Belden, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Mullin, Bret |e verfasserin |4 aut | |
| 700 | 1 | |a Magee, Devon |e verfasserin |4 aut | |
| 700 | 1 | |a Mikell, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Lokesh |e verfasserin |4 aut | |
| 700 | 1 | |a Powers, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Curcio, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Daskalakis, Constantine |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, Mark |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life (Basel, Switzerland) |d 2011 |g 12(2022), 3 vom: 19. März |w (DE-627)NLM243284799 |x 2075-1729 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:3 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/life12030453 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 3 |b 19 |c 03 | ||